Analytical Data
-
基因名
IFN-alpha 14/IFNA14
- Application
-
别名
Interferon alpha-H
-
种属
Human
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P01570
-
表达区间
24-189aa
-
蛋白长度
Partial
-
分子量
35.7 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interferon-alpha 14 (IFN-alpha 14, also known as IFNA14) is a member of the type I interferon family, recognized for its potent antiviral and immunomodulatory properties. As an essential part of the immune response to viral infections, IFNA14 is produced by various immune cells upon recognition of pathogens. Research into IFNA14 has gained traction due to its potential therapeutic applications in treating viral diseases, certain cancers, and autoimmune disorders. Unlike other interferons, IFNA14 has distinct receptor affinity and signaling pathways, making it an intriguing subject for biopharmaceutical development. Studies have highlighted its efficacy in enhancing cytotoxic T-cell responses and modulating the activity of natural killer cells. Moreover, recombinant IFNA14 proteins are being explored for their ability to improve antiviral responses while potentially minimizing the side effects commonly associated with other interferon therapies. The ability to produce recombinant IFNA14 has opened avenues for investigating its clinical benefits, optimizing its formulation, and evaluating its role in combination therapies. Overall, understanding the underlying mechanisms of IFNA14 and developing effective recombinant forms can contribute significantly to advancing therapeutic strategies against various diseases, emphasizing the need for continued research in this area.
